If our in vitro results can be translated to humans, they suggest that poziotinib, in combination with specific anticancer drugs such as irinotecan, SN-38 and 5-FU [30], could be used to combat ABCG2- and ABCB1-mediated MDR in patients with CRC. The gene discussed is ABCB1; the disease is colorectal carcinoma.